Dear NNPDF Families and Friends,
Recently, the leadership of the NNPDF was approached by representatives from Genzyme (A Sanofi Company) regarding a ground-breaking opportunity for our Niemann-Pick Type B patient community. Representatives from the United States Food and Drug Administration (FDA) involved with the regulatory aspects of the upcoming Genzyme pediatric and adult Enzyme Replacement Therapy Clinical Trials had asked to meet with members of the NPD Type B patient community.
To view the full list of attendees & a recap of the meeting, which was held this past Wednesday, April 29th, 2015, visit the NNPDF Newsline web page: http://www.nnpdf.org/Newsline2015.html#FDA
No comments:
Post a Comment